Trial Profile
A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of Crohn's disease and NASH
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2019
Price :
$35
*
At a glance
- Drugs Foralumab (Primary)
- Indications Crohn's disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- 16 Sep 2019 According to a Tiziana Life Sciences media release, the U.S. Food and Drug Administration (FDA) has allowed the initiation of this study.
- 04 Apr 2019 According to a Tiziana Life Sciences media release, This single-site clinical study will be conducted at the Brigham and Women's Hospital (BWH), Harvard Medical School.
- 04 Apr 2019 According to a Tiziana Life Sciences media release, On 20 March 2019, the Company announced that it had submitted an IND to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.